Loading
A phase 1/2 trial of Lutetium-177 dotatate, FAP-2286, Atezolizumab in small-cell lung cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab is a phase 1/2 interventional study registered as NCT05142696 by Novartis Pharmaceuticals, with 55 participants enrolled, started 2022-07-13 and due to reach its primary completion in 2028-03-07. Interventions recorded: [177Lu]Lu-DOTA-TATE, Atezolizumab, [68Ga]Ga-DOTA-TATE, Carboplatin, Etoposide. Conditions listed: Extensive Stage Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Novartis, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/